亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

美國Epitome Biosystems
繼今年2月初以2200萬美金成功收購Guava Technologies (Guava)*之后，密理博公司再度出資收購Epitome Biosystems’ EpiTag?技術。該項技術的收購將使密理博生物科學部門進一步拓展在multiplex immunoassay液相芯片檢測方面的實力，為科學家提供更廣闊的細胞信號傳導解決方案。

密理博公司藥物研發部門( Drug Discovery) VP, Rick Ryan強調: “ multiplex是密理博公司其中一條增長最快速的產品線，對EpiTag技術的收購，將加速產品的發展以及在市場上的增長。用戶希望更清楚了解在癌癥，糖尿病等各種疾病中細胞信號傳導通路的重要性。EpiTag技術將使我們深入發展液相芯片技術，尤其是在先前細胞研究中難以檢測和定量的部分.”

由于缺少對細胞內目標高度特異性的抗體，科學家一直以來在推進液相芯片細胞信號檢測方面舉步為艱。EpiTag技術使用分析復雜生物資料的途徑來開發高質量的抗體，使其更特異，更具選擇性。密理博公司將開發一系列全新的液相芯片免疫檢測試劑盒，以方便科學研究者更有效地檢測、分析蛋白質與細胞信號通路。

Epitome Biosystems, Inc. develops and commercializes innovative protein measurement products and services to increase the productivity of drug discovery and development. The Company’s products generate valuable information about the cell signaling network, which is a key interface for monitoring drug action and understanding disease. By delivering high-value information on cell signaling networks in a condensed time frame, Epitome’s products and services are driving new research approaches for the development of drugs and diagnostics.

The Company’s products include profiling chips and assay kits, based on proprietary EpiTag? technology, and mass spectrometry-based discovery partnerships (Q-SONAR?). EpiTag? profiling chips and multiplex assays provide highly specific, quantitative measurements of the cell signaling network. Q-SONAR? generates quantitative, broad-based analyses to elucidate cell network dynamics and connectivity, identify potential new targets/biomarkers and more comprehensively assess on- and off-target effects of drugs. Epitome’s technology is validated, scaleable and can be applied broadly across the drug discovery and development continuum and translated to clinical biomarker applications. Epitome partners with pharmaceutical and biotechnology companies to deliver off-the-shelf products and customized solutions.